The initial success of Viagra undeniably reshaped the drug landscape, but investing in companies strongly reliant on off-patent versions presents a challenging picture. Despite early profits were impressive, the expiration of patents and the appearance of less expensive alternatives have eroded sales. Thus, a thorough analysis of ongoing financial